| Autor: |
Donati, G, La Manna, G, Cianciolo, G, Grandinetti, V, Carretta, E, Cappuccilli, M, Panicali, L, Iorio, M, Piscaglia, F, Bolondi, L, Colì, L, Stefoni, S |
| Přispěvatelé: |
Donati, G, La Manna, G, Cianciolo, G, Grandinetti, V, Carretta, E, Cappuccilli, M, Panicali, L, Iorio, M, Piscaglia, F, Bolondi, L, Colì L, Stefoni, S |
| Rok vydání: |
2013 |
| Předmět: |
|
| Zdroj: |
Artificial organs. 38(2) |
| ISSN: |
1525-1594 |
| Popis: |
Acute liver failure and acute-on-chronic liver failure still show a poor prognosis. The molecular adsorbent recirculating system (MARS) has been extensively used as the most promising detoxifying therapy for patients with these conditions. Sixty-four patients with life-threatening liver failure were selected, and 269 MARS treatments were carried out as a bridge for orthotopic liver transplantation (OLT) or for liver function recovery. All patients were grouped according to the aim of MARS therapy. Group A consisted of 47 patients treated for liver function recovery (median age 59 years, range 23-82). Group B consisted of 11 patients on the waiting list who underwent OLT (median age 47 years, range 32-62). Group C consisted of 6 patients on the waiting list who did not undergo OLT (median age 45.5 years, range 36-54, P = 0.001). MARS depurative efficiency in terms of liver toxins, cytokines, and growth factors was assessed together with the clinical outcome of the patients during a 1-year follow-up. Total bilirubin reduction rate per session (RRs) for each MARS session was 23% (range 17-29); direct bilirubin RRs was 28% (21-35), and indirect bilirubin RRs was 8% (3-21). Ammonia RRs was 34% (12-86). Conjugated cholic acid RRs was 58% (48-61); chenodeoxycholic acid RRs was 34% (18-48). No differences were found between groups. Hepatocyte growth factor (HGF) values on starting MARS were 4.1 ng/mL (1.9-7.9) versus 7.9 ng/mL (3.2-14.1) at MARS end (P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text